A retrospective study on the efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) and with/without immunotherapy in intermediate-advanced hepatocellular carcinoma (HCC).

被引：0
|
作者：
Chen, Cong
Fu, Shouzhong
Zhao, Suming
Yuan, Hongxin
Dai, Feng
Gu, Weiwei
Gu, Zhuxin
Shi, Rongfeng
Yang, Xiaohu
Lu, Xiaohua
Jia, Pengfei
Si, Luyi
Zhao, Hui
机构：
[1] Affiliated Hosp Nantong Univ, Nantong, Peoples R China
[2] Nantong Univ, Nantong Peoples Hosp 3, Nantong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16171
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases
    Wang, Xinhao
    Yang, Yefa
    MEDICINE, 2024, 103 (20) : E38174
  • [22] Efficacy and safety of donafenib combined with transcatheter arterial chemoembolization (TACE) and anti-PD1 antibody for the treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective study
    Ge, Naijian
    Wang, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC)
    Zhou, Jian
    Yan, Zhiping
    Wang, Zheng
    Qiu, Shuang-Jian
    Yang, Minjie
    Zhu, Kai
    Yi, Yong
    Yu, Lei
    Sun, Yun-Fan
    Zhang, Bo
    Yu, Jiaze
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study
    Patidar, Yashwant
    Chandel, Karamvir
    Condati, Naveen K.
    V. Srinivasan, Shyam
    Mukund, Amar
    Sarin, Shiv K.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (03) : 745 - 754
  • [25] Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
    Haohao Lu
    Bin Liang
    Xiangwen Xia
    Chuansheng Zheng
    BMC Cancer, 23
  • [26] Efficacy and safety of transarterial chemoembolization in patients with advanced stages of hepatocellular carcinoma
    Promjunyakul, Benjarat
    Bunchorntavakul, Chalermrat
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 351 - 351
  • [27] Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study
    Liu, Changfu
    Xing, Wenge
    Si, Tongguo
    Yu, Haipeng
    Guo, Zhi
    ONCOTARGET, 2017, 8 (59) : 100734 - 100745
  • [28] Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study
    Kwon, Joon Ho
    Kim, Gyoung Min
    Han, Kichang
    Won, Jong Yun
    Kim, Man Deuk
    Lee, Do Yun
    Lee, Junhyung
    Choi, Woosun
    Kim, Yong Seek
    Kim, Do Young
    Han, Kwang-Hyub
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2018, 41 (03) : 459 - 465
  • [29] Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study
    Joon Ho Kwon
    Gyoung Min Kim
    Kichang Han
    Jong Yun Won
    Man Deuk Kim
    Do Yun Lee
    Junhyung Lee
    Woosun Choi
    Yong Seek Kim
    Do Young Kim
    Kwang-Hyub Han
    CardioVascular and Interventional Radiology, 2018, 41 : 459 - 465
  • [30] Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
    Qin, Jian
    Huang, Yusheng
    Zhou, Hanjing
    Yi, Shouhui
    FRONTIERS IN ONCOLOGY, 2022, 12
12345